<DOC>
	<DOCNO>NCT00198133</DOCNO>
	<brief_summary>To study efficacy Alimta single agent thymic cancer</brief_summary>
	<brief_title>Phase II Study Alimta ( Pemetrexed ) Treatment Advanced Thymoma Thymic Carcinoma</brief_title>
	<detailed_description>The broad range clinical activity thymic carcinoma make likelihood detect efficacy single agent premetrexed reasonable objective since malignancy relatively slow grow exhibit broad range chemosensitivity antineoplastic agent .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm invasive , recurrent metastatic thymoma thymic carcinoma amenable potentially curative therapy surgery . Original biopsy tumor sufficient diagnose unless otherwise clinically indicate . Patients must measurable disease least one bidimensional measurable lesion . Any scan xrays use document measurable disease must obtain 6 week prior registration . Patients may prior chemotherapy metastatic disease Adequate organ function define : bili &lt; /=1.5 ; calc . crt clr &gt; /=45 ; hematologicgranulocytes &gt; /=1500 &amp; plt &gt; /=100K . Patients receive stable dose corticosteroid myasthenia gravis eligible . ECOG performance status 0 1 Acute intercurrent infection complication pregnancy lactate patient Inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( 8day period longacting agent . Presence clinically relevant thirdspace fluid collection control procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Thymoma</keyword>
	<keyword>Thymic Carcinoma</keyword>
</DOC>